FDA broadens label for Amgen's Uplizna as it enters rare disease competition
FDA broadens label for Amgen's Uplizna as it enters rare disease competition
Body unavailable. Use the original source.
FDA broadens label for Amgen's Uplizna as it enters rare disease competition